Drugs / SETILEUTON
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00768170 | Sep 2008 → May 2009 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00751413 | Aug 2008 → Jan 2009 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00646789 | May → Jul 2008 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT00404313 | Jan 2008 → Jun 2009 | asthma | Merck Sharp & Dohme LLC | Terminated | Met primary |
| Phase 2 | NCT00418613 | Jan 2008 → Mar 2009 | chronic obstructive pulmonary disease | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT00421278 | Nov → Dec 2006 | atherosclerosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SETILEUTON | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105653 ↗ |
| Known as | MK-0633 | “The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma.” PMID 21945511 ↗ Sep 20117“MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease.” PMID 20970976 ↗ Nov 2010 “MK0633 100mg capsules qd for a 12-wk treatment period.” NCT00418613 ↗ |
| Action | Inhibit | “The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma.” PMID 21945511 ↗ Sep 2011 |
| Modality | Small molecule | — CHEMBL2105653 ↗ |
| Route | Oral | “MK0633 100mg capsules qd for a 12-wk treatment period.” NCT00418613 ↗ |